Complement Pharma, focused on complement inhibition to modify neurodegenerative disease progression.
First Therapeutic Product Focus
Complement Pharma is developing a line of products based on proprietary monoclonal antibodies to inhibit formation of the Membrane Attack Complex (MAC) part of the complement pathway.
Complement Pharma is developing new therapies for neurodegenerative indications.
Complement Pharma is a biotech company focusing on complement inhibition to modify neurodegenerative disease progression. The Company was founded in 2017 to translate the opportunities of complement (C6) inhibition into clinical products for patients.